期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小分子酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的研究进展 被引量：2

Advances of small-molecule tyrosine kinase inhibitors on brain metastasis of non-small cell lung cancer
下载PDF
导出
摘要 脑转移是影响晚期非小细胞肺癌患者预后的重要因素,全脑放疗和立体定向放疗是常用的治疗手段。随着小分子酪氨酸激酶抑制剂在非小细胞肺癌治疗上获得成功,陆续有其治疗非小细胞肺癌脑转移及脑膜转移的研究。本文就小分子酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的机理、临床应用以及治疗失败后的处理等方面作一综述。 Brain metastasis is a major clinical prognosis factor for advanced non-small cell lung cancer. Now the whole brain radiotherapy and stereotactic radiosurgery are common treatments of it. With the success of small-molecule tyrosine kinase inhibitors in non-small cell lung cancer, recent clinical researches have shown their activities against brain and leptomeningeal metastases. The mechanisms, clinical applications of small-molecule tyrosine kinase inhibitors on brain metastasis and therapeutic choice after the failure will be reviewed in this article.
作者 黄伟 王琳
机构地区 南京中医药大学第一临床医学院 解放军八一医院全军肿瘤中心内科
出处 《临床肿瘤学杂志》 CAS 2011年第8期755-759,共5页 Chinese Clinical Oncology
关键词 小分子酪氨酸激酶抑制剂 非小细胞肺癌 脑转移 耐药 Small-molecule tyrosine kinase inhibitor Non-small cell lung cancer Brain metastasis Drug resistance
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Ma S, Xu Y, Deng Q, et al. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and ge- fitinib in a Chinese population [ J ]. Lung Cancer, 2009,65 ( 2 ) : 198 - 203.
  • 2Li Z,Lu J,Zhao Y, et al. The retrospective analysis of the frequen- cy of EGFR mutations and the efficacy of gefitinib in NSCLC pa- tients with brain metastasis [ J]. J Ctin Oncol, 2011, 29 (Suppl) : a18065.
  • 3Villano JL,Maucer AM,Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain [ J ]. Ann On- col ,2003,14:656 - 658.
  • 4Dhruva N, Socinski MA. Carcinomatous meningitis in non-small cell lung cancer: response to high-dose erlotinib [ J ]. J Clin On-col,2009,27 ( 22 ) :31 - 32.
  • 5Hata A, Kaji R, Fujita S, et al. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer [ J ]. J Thorac Oncol, 2011,6 ( 3 ) : 653 - 654.
  • 6Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glycoprotein(ABCB1 ) and breast cancer resistance protein(ABCG2)-mediated active efflux[ J]. J Pharma- cot Exp Ther,2010,334( 1 ) :147 -155.
  • 7Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomenings in patients with non- small cell lung carcinoma after response to gefitinib [ J ]. Cancer, 2005,103 ( 11 ) :2344 - 2348.
  • 8Wang M, Jing Z, Minjiang C. Cerebral penetration of gefitinib in patients with lung adenocarcinoma [ J ]. J Clin Oncol, 2011,29 (Suppl) : a7608.
  • 9蔡俊明,丘昭华,刘家伶,蔡佩君,彭瑞鹏.吉非替尼(Gefitinib)对非小细胞肺癌的脑部转移具有疗效[J].中国肺癌杂志,2004,7(4):298-304. 被引量：20
  • 10Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib a- chieves therapeutic concentrations in CSF and is effective in lepto- meningeal metastases from epidermal growth factor receptor mutant lung cancer [ J ]. J Neurooncol, 2010,99 ( 2 ) : 283 - 286.

二级参考文献56

共引文献42

同被引文献24

  • 1郑康,吴刚,王硕,鲍圣德,周良辅.神经外科术后早期癫痫的治疗及病因研究[J].中华神经医学杂志,2006,5(1):73-75. 被引量：27
  • 2Ranjan T, Abrey LE. Current management of metastatic brain disease[J]. Neurotherapeutics, 2009,6 (3) : 598-6113.
  • 3Sequist LV, Martins RG, Spigel D,etal. First-line gefitinib in patients with advanced nomsmall-cell lung cancer harboring so matic EGFR mutations[J]. J Clin Oncol, 2008,26(20) : 2442- 2449.
  • 4Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small- cell lung cancer[J]. J Clin Oncol, 2007, 25(5) : 587-595.
  • 5Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by pos- itren emission tomography in a patient harboring a mutation in the epi- dermal growth factor receptor[ J ]. J Thorac Oncol, 2011, 6 ( 7 ) : 1287-1289.
  • 6Togashi Y, Masago K, Fukudo M, et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation [ J ]. Cancer Chemother Pharmacol, 2011,68(4) : 1089-1092.
  • 7Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cere- brespinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-42(}[ J]. Cfin Cancer Res, 2007, 13(5) : 1511-1515.
  • 8Fukuhara T, Saijo Y, Sakakibara T, et al. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adeno- carcinoma harboring a mutated EGF receptor gene[J]. Tohoku J Exp Med, 2008, 214(4) : 359-363.
  • 9Zhao J, Chen M, Zhong W, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocareinoma [ J ]. Clin Lung Cancer, 2013, 14(2) : 188-193.
  • 10Wu YL, Zhou C, Chang Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asympto- marie brain metastases: a phase Ⅱ study ( CTONG-0803 ) [ J]. AnnOneol, 2013, 24(4) : 993-999.

引证文献2

二级引证文献11

临床肿瘤学杂志
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部